600557 Jiangsu Kanion Pharmaceutical
- 19.85
- -0.82-3.97%
Jiangsu Kanion Pharmaceutical News
Kangyuan Pharmaceutical (600557): A leader in innovative traditional Chinese medicine that is expected to gradually reverse
Key investment event: “Randomized, open, multi-center clinical study on the efficacy and safety of cooling and humidifying granules versus nematvir tablets/ritonavir tablets in the treatment of novel coronavirus infections in adults” were recently released in Beijing. Research results show that new
Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Most readers would already be aware that Jiangsu Kanion PharmaceuticalLtd's (SHSE:600557) stock increased significantly by 15% over the past three months. We wonder if and what role the company's fi
Kangyuan Pharmaceutical (600557.SH): A total cost of 17.34 million yuan to buy back 0.1733% of shares
Gelonghui, May 7, 丨 Kangyuan Pharmaceutical (600557.SH) announced that as of April 30, 2024, the company had repurchased a total of 1,013,600 shares, accounting for 0.1733% of the company's total share capital. The highest purchase price was 19.83 yuan/share, the lowest price was 16.27 yuan/share, and the total amount paid was 17,344,891.23 yuan (including transaction fees).
Express News | Kangyuan Pharmaceutical: Received a notice of approval for the clinical trial of Shichimi Fatty Liver Granules
Jiangsu Kanion PharmaceuticalLtd's (SHSE:600557) Earnings May Just Be The Starting Point
Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) earnings announcement last week was disappointing for investors, despite the decent profit numbers. We have done some analysis and have found so
Wanlian Securities released a research report on April 19 stating that Kangyuan Pharmaceutical (600557.SH) was given a purchase rating. The main reasons for the rating include: 1) high growth in oral liquids and gels; 2) year-on-year increase in gross mar
Wanlian Securities released a research report on April 19 stating that Kangyuan Pharmaceutical (600557.SH) was given a purchase rating. The main reasons for the rating include: 1) high growth in oral liquids and gels; 2) year-on-year increase in gross margin of tablets and capsules, while the remaining dosage forms have decreased to varying degrees; 3) increased R&D investment and cost rate optimization. (Mainichi Keizai Shimbun)
Kangyuan Pharmaceutical (600557) Review Report: Outstanding Performance of Oral Medications, Cost Optimization
Key elements of the report: On April 13, 2024, the company released its 2024 quarterly report. 2024Q1, the company achieved operating income of 1,359 million yuan (+0.48%) and net profit of 148 million yuan to mother (
China Post Securities released a research report on April 17 stating that Kangyuan Pharmaceutical (600557.SH) was given a purchase rating. The main reasons for the rating include: 1) revenue: rapid growth in oral liquid, slight decline in injections due t
China Post Securities released a research report on April 17 stating that Kangyuan Pharmaceutical (600557.SH) was given a purchase rating. The main reasons for the rating include: 1) revenue: rapid growth in oral liquid, slight decline in injections due to a high base; 2) profit: gross margin declined slightly, rate control was good, and profitability was stable; 3) continuous optimization of operational efficiency, good repayment, and sufficient cash; 4) R&D results continued to be implemented. (Mainichi Keizai Shimbun)
Kangyuan Pharmaceutical (600557): Recovery of oral formulations with excellent report quality
Core idea On the evening of April 12, the company released its report for the first quarter of 2024, achieving operating income of 1,359 million yuan, an increase of 0.48% over the previous year; net profit to mother of 148 million yuan, an increase of 4.67% over the previous year.
Kangyuan Pharmaceutical (600557): 2024Q1 oral liquid regains rapid growth, steady profitability, and operational efficiency optimization
Investment Highlights On April 12, the company released its report for the first quarter of 2024:2024Q1 revenue of 1.36 billion yuan (+0.48%), net profit to mother of 148 million yuan (+4.67%), deducting non-net profit1
On April 15, Dongfang Wealth Securities released a research report stating that Kangyuan Pharmaceutical (600557.SH) was given an increase in its holdings rating. The main reasons for the rating include: 1) performance continues to grow under a high base;
On April 15, Dongfang Wealth Securities released a research report stating that Kangyuan Pharmaceutical (600557.SH) was given an increase in its holdings rating. The main reasons for the rating include: 1) performance continues to grow under a high base; 2) the company's products are rich in basic medicine and medical insurance; 3) continuous investment and remarkable results in R&D; 4) reasonable cost control without controlling talent investment. (Mainichi Keizai Shimbun)
Huafu Securities released a research report on April 14 stating that Kangyuan Pharmaceutical (600557.SH) was given a purchase rating and the target price was 28 yuan. The main reasons for the rating include: 1) achieving positive growth under the high Q1
Huafu Securities released a research report on April 14 stating that Kangyuan Pharmaceutical (600557.SH) was given a purchase rating and the target price was 28 yuan. The main reasons for the rating include: 1) achieving positive growth under the high performance base of Q1, and strong oral liquid performance; 2) strengthening academic leadership and continuing enrichment of the Chinese medicine innovation pipeline; 3) equity incentives guide annual goals, reflecting the company's development confidence; 4) the division's equity incentive goals are: based on 2023 revenue, the 2024 revenue growth rate is not less than 18%, or based on 2023 net profit, the net profit growth rate in 2024 is not less than 20%; after 2023
Express News | Since April, nearly 10 listed companies have announced illegal short-term transactions involving senior directors and supervisors
Guolian Securities released a research report on April 14 stating that Kangyuan Pharmaceutical (600557.SH) was given a purchase rating and the target price was 25.72 yuan. The main reasons for the rating include: 1) Jin Zhen oral liquid and muscle pain re
Guolian Securities released a research report on April 14 stating that Kangyuan Pharmaceutical (600557.SH) was given a purchase rating and the target price was 25.72 yuan. The main reasons for the rating include: 1) Jin Zhen oral liquid and muscle pain relief gel are sold well; 2) the product pipeline is rich, and R&D is progressing smoothly. (Mainichi Keizai Shimbun)
Kangyuan Pharmaceutical (600557): Maintaining positive growth under a high base, oral liquid performed well
Investment highlights: Positive growth was achieved under a high Q1 performance base, and oral liquid performance was strong. Kangyuan Pharmaceutical achieved total revenue of 1.36 billion yuan in the first quarter of 2024, up 0.5% year on year; net profit to mother was 150 million yuan, up year on year
Kangyuan Pharmaceutical (600557): The oral solution that met expectations performed well
Key investment events: Kangyuan Pharmaceutical released its 2024 quarterly report. During the reporting period, it achieved revenue of 1,359 million yuan (+0.48% year over year) and net profit to mother of 148 million yuan (+4.67% year over year), after deducting net profit from non-return to mother
Express News | Kangyuan Pharmaceutical: Received a notice of approval for the clinical trial of Qiangqin granules
Kangyuan Pharmaceutical (600557.SH): Net profit of 148 million yuan in the first quarter increased 4.67% year-on-year
Gelonghui, April 12 | Kangyuan Pharmaceutical (600557.SH) released its first quarter report. Operating revenue was 1,359 million yuan, up 0.48% year on year, net profit of 148 million yuan, up 4.67% year on year, after deducting non-net profit of 140 million yuan, up 0.20% year on year, with basic earnings per share of 0.26 yuan.
Is There An Opportunity With Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) 36% Undervaluation?
Key Insights The projected fair value for Jiangsu Kanion PharmaceuticalLtd is CN¥31.77 based on 2 Stage Free Cash Flow to Equity Current share price of CN¥20.20 suggests Jiangsu Kanion Pharmaceutica
Kangyuan Pharmaceutical (600557.SH): A total cost of 14.12 million yuan to buy back 0.15% of shares
Gelonghui, April 1, 丨 Kangyuan Pharmaceutical (600557.SH) announced that as of March 31, 2024, the company had repurchased a total of 849,300 shares, accounting for 0.15% of the company's total share capital. The highest transaction price purchased was 17.93 yuan/share, the lowest transaction price was 16.27 yuan/share, and the total amount paid was 14,121,888.36 yuan.
Analysis
Price Target
No Data
